Apeiron Biologics and Columbia University enter exclusive license agreement

 

VIENNA, Austria I February 16, 2016 I APEIRON Biologics AG (“Apeiron”) announced today that it has entered into an exclusive license agreement with Columbia University through their technology transfer office, Columbia Technology Ventures. Under the terms of the agreement, Apeiron obtains worldwide exclusive rights to develop and commercialize active cellular immunotherapies under the licensed patents, which cover the inhibition of Cbl-b in T cells for the treatment of cancer.

 

Subscribe to get the latest news